A Phase 3, Multicenter, Double-Blind, Placebo-controlled Study Assessing the Efficacy andSafety of Olomorasib in Combination with Standard of Care Immunotherapy in Participants withResected or Unresectable KRAS G12C-Mutant, Non-Small Cell Lung Cancer -

The purpose of this research study is to learn more about a new medicine called olomorasib, to see if it can help treat lung cancer. We want to see if olomorasib, when used along with standard immunotherapy (pembrolizumab or durvalumab), works well for people with a certain type of lung cancer called KRAS G12C-mutated non-small cell lung cancer (NSCLC) after they’ve had their first treatment. In this study, some people will get olomorasib, and others will get a placebo. Olomorasib is the investigational study drug in this study, and it is not approved by the United States Food and Drug Administration (FDA). A placebo is a pill that looks like olomorasib but doesn’t have any active medicine in it. Everyone in the study will also get their usual immunotherapy.

Are you Eligible? (Inclusion Criteria)

• Are an acceptable age to provide informed consent according to local regulations and are at least 18 years of age. 2. Must have a confirmed diagnosis of non-small cell lung cancer (NSCLC) based on lab tests of tissue or cell samples 3. Are capable of giving signed informed consent and being compliant with the requirements and restrictions listed in the ICF and in this protocol.